The antibody R22 is directed against human CD39. The antibody has not been tested for cross reactivity with other species.
Immunogen
R22 is a rat monoclonal IgG1 antibody derived by fusion of SP2/0 mouse myeloma cells with splenocytes from a WAG/Rij rat immunized with JY cells, a human B lymphoblastoid cell line.
The R22 antibody is suitable for the detection of human CD39 antigen by flow cytometry. Human spleen is suitable as a positive control. Optimal antibody dilutions for the different applications should be determined by titration.
Restrictions
For Research Use only
Buffer
Each vial contains 100 μL 1 mg/mL purified monoclonal antibody in phosphate buffered saline (PBS) containing 0.09 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
CD39 is a transmembrane cell surface protein, which is a member of the ecto-nucleoside triphosphate diphosphohydrolase (ENTPDase) family. The CD39 Molecule is primarily involved in the metabolism of purine nucleotides, converting extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP). In conjunction with CD73 (5' nucleotidase), CD39 plays a key role in regulating immunity and inflammation through the production of adenosine and purinergic signalling pathways. In addition, CD39 is reported to mediate B cell homotypic adhesion and inhibit ADP-induced platelet aggregation. CD39 was originally identified on Epstein Barr virus transformed B cell lines and described as a B-cell activation marker. However, subsequent studies have shown that CD39 is also expressed on activated T-cells, T-regulatory cells, natural killer cells, tissue macrophages and endothelial cells. Increased expression of CD39 has also been reported in cases of chronic lymphocytic leukaemia and several solid tumours including colorectal and pancreatic cancer suggesting a potential role for CD39 in tumour development and progression.